Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Scroll Up
Scroll Down

Approaches to Screening for Risk from Pharmaceuticals in Drinking Water and Prioritization for Further Evaluation
Bookmark and Share


EPA

The presence of pharmaceuticals in drinking water is not a new issue. In the 1970’s, several researchers reported the presence of clofibric acid, a breakdown product of several blood lipid regulators, and salicylic acid, a breakdown product of aspirin, in waste water. However, as analytical techniques grew more sensitive over the years, many more pharmaceuticals have been detected in ambient water, wastewater, and drinking water.

During 1999-2000, the U.S. Geological Survey carried out the first national survey of the occurrence of pharmaceuticals, hormones, and other chemicals in 139 streams from 30 states. A total of 95 contaminants were targeted, with 80 percent of the streams testing positive for one or more contaminants.

Pharmaceuticals enter water through: flushing unused medications down the toilet or sink; excreting unabsorbed medications into the sewage system; farm animals excreting veterinary drugs into fields where they run off into lakes and streams; and commercial improper disposal methods. Conventional water and wastewater treatment methods allow many pharmaceuticals to pass through unchanged, entering the environment and ultimately the drinking water.

One problem with assessing risk of pharmaceuticals in drinking water is the very large number of pharmaceuticals in use today. Information on the occurrence of pharmaceuticals in drinking water is available only for a limited number of compounds. In addition, many pharmaceuticals are biologically degraded to active metabolites that have not been evaluated. One problem with assessing risk of pharmaceuticals in drinking water is the very large number of pharmaceuticals in use today. Information on the occurrence of pharmaceuticals in drinking water is available only for a limited number of compounds. In addition, many pharmaceuticals are biologically degraded to active metabolites that have not been evaluated.

A number of different approaches have been suggested and published in the peer reviewed literature for screening and prioritizing the hazard posed by low concentrations of pharmaceuticals in drinking water. This white paper summarizes and evaluates a number of risk assessment approaches (including EPA’s current approach), that EPA is aware of, that have been described in the literature. This paper is not a comprehensive compilation of all published approaches. In addition, this paper describes EPA’s current activities and research strategy for pharmaceuticals in water.

Further Information

Related Content

Fracking Hasn't Caused Widespread Harm to Water
Assessment shows hydraulic fracturing activities have not led to widespread, systemic impacts to drinking water resources and identifies important vulnerabilities to drinking water resources.
Monday, June 08, 2015
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!